Biocure Technology Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BICTF research report →
Price Chart
About the company
Biocure Technology Inc. , along with its subsidiary, is dedicated to the development and market introduction of biopharmaceutical technologies, particularly those leveraging recombinant proteins and ranibizumab. The company's therapeutic pipeline features Interferons-ß, which are being advanced for the treatment of multiple sclerosis.
- CEO
- Yee Sing Cheng
- IPO
- 2018
- Employees
- 3
- HQ
- Vancouver, BC, CA
Get TickerSpark's AI analysis on BICTF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $379.09K
- P/E
- -2.06
- PEG
- 0.07
- P/S
- 0.00
- P/B
- 0.18
- EV/EBITDA
- -5.94
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -6.94%
- ROIC
- -5.57%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-90,789
- Net Income
- $-102,776+60.8%
- EPS
- $-0.01+74.5%
- OCF Growth
- -557632.4%
- FCF Growth
- -557603.3%
- 52W High
- $0.07
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- 3.78
- RSI (14)
- 46
- Avg Volume
- 22
No earnings-call transcripts are available for BICTF yet.
- Free Float
- 57.9%
- Shares Outstanding
- 37.91M
- Float Shares
- 21.95M
Our BICTF coverage
Recent articles, reports, and earnings notes.
No research on BICTF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BICTF report →Biocure Technology Inc. Announces Adoption of Semi-Annual Reporting
thenewswire.com · May 8
CSE Bulletin: Consolidation - Biocure Technology Inc. (CURE.X)
newsfilecorp.com · Oct 23
Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology
globenewswire.com · Sep 18
Biocure Technology Inc. Enters into Exclusive Letter Agreement to Acquire Atriva Therapeutics GmbH in Reverse Takeover Transaction
newsfilecorp.com · Sep 18
BioCure Technology Inc. Announces New President, Appointment of Capital Markets Advisor and Grant of Stock Options
newsfilecorp.com · Jul 22
BioCure Technology Inc. Announces Closing of Financing
newsfilecorp.com · Jul 14
BiocurePharm, Korea (BPK) Signs MOU With Symbasis GmbH to Develop CAR-T Therapy for Chronic Lymphocyte Leukemia (CLL)
newsfilecorp.com · Jan 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.